HAG预激方案治疗老年高危MDS的临床疗效分析

Clinical Efficacy of HAG Regimen for Elderly Patients with High-risk Myelodysplastic Syndrome

目的探讨HAG预激方案治疗老年高危骨髓增生异常综合征(MDS)患者的疗效。方法高危MDS患者24例,随机分为HAG组和对照组,每组12例。HAG组采用HAG预激方案治疗,对照组采用标准化疗方案治疗。化疗前后监测血常规、肝肾功能、心电图、骨髓等变化,统计疗效和不良反应。结果性别、体质量(BMI)、年龄、经济收入、婚姻状况、应激状态、高血压、职业、是否吸烟、是否饮酒、民族、糖尿病史、冠心病史、WHO分型和乳酸脱氢酶均与HAG预激方案疗效无关(P>0.05)。多因素分析显示性别、WHO分型和乳酸脱氢酶均与HAG预激方案疗效无关(P>0.05)。HAG组不良反应较轻。结论 HAG预激方案治疗老年高危MDS患者,疗效显著,不良反应较轻,安全性高,适用于老年高危MDS患者。

Objective To investigate the curative effect of HAG regimen for elderly patients with high-risk myelodysplastic syndrome( MDS). Methods 24 cases of elderly patients with high-risk MDS were randomly divided into the HAG group and the control group,with 12 cases in each. The HAG group received HAG regimen,and the control group received standard chemotherapy. Changes of blood routine,liver and rental function,electrocardiogram,and marrow were collected. Curative effect and adverse reactions were recorded. Results Gender,BMI,age,smoking,drinking WHO classification and LDH was not correlated with efficacy of HAG( P > 0. 05). Multiple factors showed that Gender,WHO classification and LDH was not correlated with curative effect of HAG( P > 0. 05). Adverse effect of HAG group was lighter. Conclusion HAG regimen on the elderly patients with high-risk myelodysplastic syndrome has significant effect,light adverse effect,high safety,and is suitable for elderly patients with high-risk myelodysplastic syndrome.